vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and PRA GROUP INC (PRAA). Click either name above to swap in a different company.
PRA GROUP INC is the larger business by last-quarter revenue ($333.4M vs $168.4M, roughly 2.0× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 13.7%). Over the past eight quarters, PRA GROUP INC's revenue compounded faster (14.2% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
PRA Group, Inc. is a publicly traded debt buyer and debt collection company based in Norfolk, Virginia. The company buys delinquent consumer debt from credit card issuers and other financial institutions at a discount and pursues collection of the full debt owed. Founded in 1996, PRA Group employs more than 3200 people in 18 countries.
ESPR vs PRAA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $333.4M |
| Net Profit | — | $56.5M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 37.7% |
| Net Margin | — | 17.0% |
| Revenue YoY | 143.7% | 13.7% |
| Net Profit YoY | — | 206.3% |
| EPS (diluted) | $0.32 | $1.47 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $333.4M | ||
| Q3 25 | $87.3M | $311.1M | ||
| Q2 25 | $82.4M | $287.7M | ||
| Q1 25 | $65.0M | $269.6M | ||
| Q4 24 | $69.1M | $293.2M | ||
| Q3 24 | $51.6M | $281.5M | ||
| Q2 24 | $73.8M | $284.2M | ||
| Q1 24 | $137.7M | $255.6M |
| Q4 25 | — | $56.5M | ||
| Q3 25 | $-31.3M | $-407.7M | ||
| Q2 25 | $-12.7M | $42.4M | ||
| Q1 25 | $-40.5M | $3.7M | ||
| Q4 24 | — | $18.5M | ||
| Q3 24 | $-29.5M | $27.2M | ||
| Q2 24 | $-61.9M | $21.5M | ||
| Q1 24 | $61.0M | $3.5M |
| Q4 25 | 50.6% | 37.7% | ||
| Q3 25 | -11.4% | -101.4% | ||
| Q2 25 | 8.6% | 29.6% | ||
| Q1 25 | -34.0% | 27.7% | ||
| Q4 24 | -6.4% | 32.1% | ||
| Q3 24 | -31.0% | 32.0% | ||
| Q2 24 | 3.5% | 31.4% | ||
| Q1 24 | 52.5% | 26.0% |
| Q4 25 | — | 17.0% | ||
| Q3 25 | -35.9% | -131.0% | ||
| Q2 25 | -15.4% | 14.7% | ||
| Q1 25 | -62.2% | 1.4% | ||
| Q4 24 | — | 6.3% | ||
| Q3 24 | -57.2% | 9.6% | ||
| Q2 24 | -83.9% | 7.6% | ||
| Q1 24 | 44.3% | 1.4% |
| Q4 25 | $0.32 | $1.47 | ||
| Q3 25 | $-0.16 | $-10.43 | ||
| Q2 25 | $-0.06 | $1.08 | ||
| Q1 25 | $-0.21 | $0.09 | ||
| Q4 24 | $-0.14 | $0.47 | ||
| Q3 24 | $-0.15 | $0.69 | ||
| Q2 24 | $-0.33 | $0.54 | ||
| Q1 24 | $0.34 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $104.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $979.9M |
| Total Assets | $465.9M | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $104.4M | ||
| Q3 25 | $92.4M | $107.5M | ||
| Q2 25 | $86.1M | $131.6M | ||
| Q1 25 | $114.6M | $128.7M | ||
| Q4 24 | $144.8M | $105.9M | ||
| Q3 24 | $144.7M | $141.1M | ||
| Q2 24 | $189.3M | $118.9M | ||
| Q1 24 | $226.6M | $108.1M |
| Q4 25 | $-302.0M | $979.9M | ||
| Q3 25 | $-451.4M | $928.5M | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.2B | ||
| Q4 24 | $-388.7M | $1.1B | ||
| Q3 24 | $-370.2M | $1.2B | ||
| Q2 24 | $-344.2M | $1.1B | ||
| Q1 24 | $-294.3M | $1.1B |
| Q4 25 | $465.9M | $5.1B | ||
| Q3 25 | $364.0M | $5.0B | ||
| Q2 25 | $347.1M | $5.4B | ||
| Q1 25 | $324.0M | $5.1B | ||
| Q4 24 | $343.8M | $4.9B | ||
| Q3 24 | $314.1M | $4.9B | ||
| Q2 24 | $352.3M | $4.7B | ||
| Q1 24 | $373.1M | $4.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-85.5M |
| Free Cash FlowOCF − Capex | — | $-90.4M |
| FCF MarginFCF / Revenue | — | -27.1% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | -1.51× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-169.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-85.5M | ||
| Q3 25 | $-4.3M | $-10.1M | ||
| Q2 25 | $-31.4M | $-12.9M | ||
| Q1 25 | $-22.6M | $-52.6M | ||
| Q4 24 | $-35.0M | $-94.6M | ||
| Q3 24 | $-35.3M | $-35.0M | ||
| Q2 24 | $-7.2M | $-29.5M | ||
| Q1 24 | $53.8M | $-73.0M |
| Q4 25 | — | $-90.4M | ||
| Q3 25 | — | $-11.3M | ||
| Q2 25 | — | $-14.2M | ||
| Q1 25 | — | $-53.5M | ||
| Q4 24 | — | $-98.6M | ||
| Q3 24 | $-35.5M | $-36.1M | ||
| Q2 24 | $-7.3M | $-30.8M | ||
| Q1 24 | $53.8M | $-73.5M |
| Q4 25 | — | -27.1% | ||
| Q3 25 | — | -3.6% | ||
| Q2 25 | — | -4.9% | ||
| Q1 25 | — | -19.8% | ||
| Q4 24 | — | -33.6% | ||
| Q3 24 | -68.7% | -12.8% | ||
| Q2 24 | -9.9% | -10.8% | ||
| Q1 24 | 39.0% | -28.8% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.4% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.3% | 0.4% | ||
| Q2 24 | 0.1% | 0.5% | ||
| Q1 24 | 0.1% | 0.2% |
| Q4 25 | — | -1.51× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.30× | ||
| Q1 25 | — | -14.37× | ||
| Q4 24 | — | -5.13× | ||
| Q3 24 | — | -1.29× | ||
| Q2 24 | — | -1.37× | ||
| Q1 24 | 0.88× | -21.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PRAA
| GB | $170.1M | 51% |
| Other | $163.3M | 49% |
